Patent claim

National Advertising Division Finds Claim that Kerasal Fungal Nail Renewal "Starts Improving Nail Appearance in Just 2 Days" Supported

Retrieved on: 
Wednesday, July 21, 2021
Nail, Advertising, Patent claim, Marketing, Nail care

NEW YORK, July 21, 2021 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs determined that Advantice Health, LLC provided a reasonable basis for the claim that its Kerasal Fungal Nail Renewal product "starts improving nail appearance in just 2 days."

Key Points: 
  • NEW YORK, July 21, 2021 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs determined that Advantice Health, LLC provided a reasonable basis for the claim that its Kerasal Fungal Nail Renewal product "starts improving nail appearance in just 2 days."
  • The claim at issue, which appeared on product packaging and in internet advertising, was originally challenged by Arcadia Consumer Healthcare in 2020.
  • In support of its claim that Kerasal Fungal Nail Renewal "starts improving nail appearance in just 2 days," the advertiser relied on the results of a four-day IHUT conducted by a third-party research company.
  • Based on the evidence provided, NAD determined that the claim that Kerasal Fungal Nail Renewal product "starts improving nail appearance in just 2 days" was supported.

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR

Retrieved on: 
Tuesday, July 13, 2021
Intellectual property law, Government, Countries, Patent law, United States patent law, Monopoly, Patent, Term of patent, Composition of matter, European Patent Convention, Outline of patents, Patent claim

The issuance of this Composition of Matter and Method of Use patent provides additional protection as MEDICE works towards the potential commercialization of ADAIR in the European Union and United Kingdom.

Key Points: 
  • The issuance of this Composition of Matter and Method of Use patent provides additional protection as MEDICE works towards the potential commercialization of ADAIR in the European Union and United Kingdom.
  • We are pleased to successfully expand our intellectual property portfolio with the issuance of this new European patent.
  • The new European patent covers composition of matter and method of use for ADAIR, with a base patent term extending until 2038.
  • ADAIR was previously granted two patents in the United States with a base patent term extending until 2037, excluding patent term extensions.

Kaplan Fox & Kilsheimer LLP and Pomerantz LLP Announce a Notice of Pendency of Class Action and Proposed Settlement in Lewis v. YRC Worldwide Inc.

Retrieved on: 
Monday, May 10, 2021
Patent claim, Patent law, Settlement

If you have not yet received the Notice and Claim Form, you may get copies of them by contacting the Claims Administrator at YRC Securities Litigation, c/o A.B.

Key Points: 
  • If you have not yet received the Notice and Claim Form, you may get copies of them by contacting the Claims Administrator at YRC Securities Litigation, c/o A.B.
  • Box 173127, Milwaukee, WI 53217; (877) 265-3022; or [email protected] .
  • If you properly exclude yourself from the Class, you will not be bound by any judgments or orders entered by the Court in the Action, and you will not be eligible to receive a payment from the Settlement.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Claims Administrator or Lead Counsel.\nRequests for the Notice and Claim Form should be made to:\n'

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of American Depositary Shares of Momo Inc. – MOMO

Retrieved on: 
Monday, April 26, 2021
Food and drink, Cuisine, Mobile technology, Momo, Intel, Patent claim, Class action, Technology

b'NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A.

Key Points: 
  • b'NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A.
  • If you have not received a detailed Notice of Pendency and Proposed Settlement of Class Action (\xe2\x80\x9cNotice\xe2\x80\x9d) and a copy of the Proof of Claim and Release Form, you may obtain copies by writing to or calling the Claims Administrator: Momo Inc. Securities Litigation, c/o Strategic Claims Services, P.O.
  • 205, Media, PA 19063; (Toll-Free) (866) 274-4004; (Fax) (610) 565-7985; [email protected].
  • You can also download copies of the Notice and submit your Proof of Claim and Release Form online at www.strategicclaims.net/Momo .

Patents Filed for Revolutionary NEW Product for Injured Insurance Claimants

Retrieved on: 
Friday, March 12, 2021
Insurance, Patent law, Patent claim, Insurance law, Tort law, Insurance industry, Types of insurance

According to David Narigon, Esq., General Counsel for RecovX Health, "In total we filed 11 unique patent claims for our inventions which together comprise the revolutionary, cloud-based mobile app for injured parties.

Key Points: 
  • According to David Narigon, Esq., General Counsel for RecovX Health, "In total we filed 11 unique patent claims for our inventions which together comprise the revolutionary, cloud-based mobile app for injured parties.
  • We term it universal, because our app will enable the injured person to organize and file their claim documents and medical documents with any insurance company at no additional cost to the claimant or insurance company.
  • "The world of third-party injury claims hasn't really changed in the last 40 years that I've been in the insurance business.
  • "We create an objective customized claim value range that an injured person should expect an insurance company to pay for their injuries.

Co-Diagnostics, Inc. Receives Enhanced U.S. Patent Protection for CoPrimer Technology Used in COVID-19 Test

Retrieved on: 
Thursday, August 20, 2020
Patent law, Patent claim, Patent, COVID-19 testing

This new patent further validates the uniqueness of the CoPrimer molecule, and provides even more comprehensive protection for all of its potential applications.

Key Points: 
  • This new patent further validates the uniqueness of the CoPrimer molecule, and provides even more comprehensive protection for all of its potential applications.
  • The additional patent covers the physical structure of the CoPrimer molecule, with more broad claims and including all configurations of a molecule with such a structure.
  • CoPrimer technology is the platform used in the Company's flagship COVID-19 testing kits, which have been deployed throughout the world and across the United States.
  • Dwight Egan, Co-Diagnostics CEO, commented, "Receiving this additional patent emphasizes the uniqueness of our CoPrimer technology.

Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock

Retrieved on: 
Monday, August 17, 2020
Civil law, Civil procedure, Class action, Lawsuit, Notice, Settlement, Patent claim

If you purchased or otherwise acquired Intellipharmaceutics common stock (trading symbol IPCI) between May 21, 2015 and July 27, 2017, inclusive, your rights may be affected by the Settlement of this Action.

Key Points: 
  • If you purchased or otherwise acquired Intellipharmaceutics common stock (trading symbol IPCI) between May 21, 2015 and July 27, 2017, inclusive, your rights may be affected by the Settlement of this Action.
  • If you have not received a detailed Notice of Pendency and Proposed Settlement of Class Action ("Notice") and a copy of the Proof of Claim and Release, you should obtain copies by writing to Intellipharmaceutics Securities Litigation, c/o Rust Consulting, Inc. 7053, P.O.
  • The Notice contains details about this Action and Settlement, including what you must do to exclude yourself from the Settlement, object to the Settlement, or file a Proof of Claim.
  • Your objection(s) must be mailed on or before October 16, 2020 to: the Court;Kahn Swick & Foti, LLC on behalf of the Lead Plaintiffs; and Counsel for the Defendants, at the following addresses:

ReelTime Doubles Down On Their IP as They Broaden Their Patent Portfolio with New Patent Filing While They Secure Additional USPTO Granted Claims in Landmark Parent Patent on Simultaneous Spherical Panorama Image and Video Capturing System

Retrieved on: 
Tuesday, August 11, 2020
Intellectual property law, Patent law, Patent application, Provisional application, United States Patent and Trademark Office, Priority right, Patent claim, Patent, Divisional patent application, Patent prosecution, Outline of patents

ReelTime VR to File Material Child Patent with New Disclosures and Claims Under Parent Application Broadening the Scope and Enforcement.

Key Points: 
  • ReelTime VR to File Material Child Patent with New Disclosures and Claims Under Parent Application Broadening the Scope and Enforcement.
  • 15/654,613 titled Simultaneous Spherical Panorama Image and Video Capturing System states that the application identified above has been examined and is allowed for issuance as a Patent.
  • The Final granted Patent is expected to be issued shortly following the Child Patent Application depending on the USPTOs schedule and workload.
  • The Patent application submitted 7/19/2017, successfully claims priority back to an earlier-filed provisional patent application to July 19, 2016.

MercuryGate Makes Automated Claim Management ‘EZ’ for 5,000+ Users Filing Nearly 600,000 Claims

Retrieved on: 
Wednesday, July 22, 2020
Professional services, Rail, Technology, Logistics, Supply chain management, Transport, Software, Finance, Operating systems, Software, Computing, Freight claim, Transport law, Twitter, Application programming interface, Patent claim

MercuryMyEZClaim consists of one comprehensive freight claim management system which organizes shipment information, creates a universally accepted claim form and manages the claim life cycle from recording payments to generation of reminder letters based on claim status.

Key Points: 
  • MercuryMyEZClaim consists of one comprehensive freight claim management system which organizes shipment information, creates a universally accepted claim form and manages the claim life cycle from recording payments to generation of reminder letters based on claim status.
  • In 2019 alone, more than 5,000 users of the MercuryMyEzClaim tool submitted almost 600,000 automated claims involving approximately 78,000 companies.
  • In addition to expanding the MercuryCarrierClaim and MercuryMyEzClaim carrier network through APIs, MercuryGate will integrate the claim filing process directly into its powerful TMS.
  • Find out why MercuryGate has set the industry standard for the most adaptable, comprehensive transportation solutions suite in the industry at: https://mercurygate.com or on Twitter at @MercuryGate .

Purchasers of Allied Nevada Gold Corporation Common Stock may be Affected by Proposed Class Action Settlement Announces Brower Piven

Retrieved on: 
Wednesday, July 22, 2020
Patent claim, Patent law

IF YOU PURCHASED OR ACQUIRED ALLIED COMMON STOCK IN THE UNITED STATES OR ON A SECURITIES EXCHANGE IN THE UNITED STATESFROM JANUARY 18, 2013, THROUGH AND INCLUDING AUGUST 5, 2013, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

Key Points: 
  • IF YOU PURCHASED OR ACQUIRED ALLIED COMMON STOCK IN THE UNITED STATES OR ON A SECURITIES EXCHANGE IN THE UNITED STATESFROM JANUARY 18, 2013, THROUGH AND INCLUDING AUGUST 5, 2013, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.
  • To share in the distribution of the Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form ("Proof of Claim") by mail postmarked no later than November 7, 2020 or electronically submitted online no later than November 7, 2020.
  • Your failure to submit or deliver your Proof of Claim form by November 7, 2020, will subject your claim to rejection and preclude your receiving any of the recovery in connection with the Settlement of this Litigation.
  • Inquiries, other than requests for the Notice or for a Proof of Claim form, may be made to Lead Counsel: